The appointments of Dr. Martin Brenner and Felipe Duran as CEO and CFO, respectively, are expected to have a positive short-term impact on iBio's stock price. Both have served in interim roles since early 2023 and have overseen key developments in the company's AI-powered biotech strategy. Their permanent appointments signal the board's confidence in their ability to lead the company in its next stage of growth.